Recent Updates — BTAI
BioXcel Therapeutics completed the sale of substantially all its neuroscience assets, including rights to IGALMI and BXCL501, to Teva Pharmaceuticals International GmbH for an upfront cash payment of $57.5 million. The transaction, approved by the U.S. Bankruptcy Court in Delaware, allows Teva to assume certain specified liabilities while BioXcel retains rights to BXCL701 and BXCL702. Proceeds were applied to repay debtor-in-possession financing as the company winds down its estate. BioXcel Therapeutics operates in the biotechnology industry, developing neuroscience treatments.
BioXcel Therapeutics filed for Chapter 11 bankruptcy protection on August 27, 2026, and entered into a $77.25 million Super-Priority Senior Secured Priming Debtor-in-Possession Credit Agreement with Oaktree Capital Management affiliates and the Qatar Investment Authority. The facility includes up to $19 million in new money term loans and $58.25 million in roll-up loans converting prepetition debt, bearing 13% annual interest and maturing January 27, 2027. Concurrently, Nasdaq notified BioXcel of its common stock delisting effective September 8, 2026, due to the bankruptcy commencement, with shares expected to trade on the Pink Limited Market. The company operates in the biopharmaceutical industry.
BioXcel Therapeutics filed voluntary petitions for Chapter 11 bankruptcy protection on August 27, 2026, in the U.S. Bankruptcy Court for the District of Delaware. The company entered into a Stalking Horse Asset Purchase Agreement with Teva Pharmaceuticals to sell substantially all assets for $57.5 million upfront cash plus up to $87.5 million in contingent milestones. BioXcel also secured Debtor-in-Possession financing totaling up to $77.25 million from Oaktree Capital Management and the Qatar Investment Authority, comprising $19 million in new money term loans and a $58.25 million roll-up of prepetition debt. Samir Saleem was appointed as Chief Restructuring Officer to oversee the process. BioXcel Therapeutics operates in the biotechnology industry, developing therapies for neurological disorders.
BioXcel Therapeutics entered into a Fourteenth Amendment to its Credit Agreement on August 24, 2026, securing $1.25 million in additional term loans and paying a $250,000 upfront fee (20% of principal). The amendment reduced the minimum liquidity covenant from $3.0 million to $250,000 but imposed stricter restrictions on out-licensing intellectual property and asset sales. The company must enter into definitive agreements by August 31, 2026, to repay all obligations or secure alternative capital acceptable to lenders. BioXcel Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.
BioXcel Therapeutics entered into the Thirteenth Amendment to its Credit Agreement and Guaranty on August 21, 2026. The amendment extends the deadline for entering definitive agreements regarding loan repayment or alternative capital solutions from August 21 to August 28, 2026. This transaction is material as it involves a critical covenant extension with lenders to avoid default under existing debt obligations. BioXcel Therapeutics operates in the biotechnology industry, focusing on the development of treatments for central nervous system disorders.
BioXcel Therapeutics entered into the Twelfth Amendment to its Credit Agreement on August 10, 2026. The amendment extends the deadline for completing a transaction resulting in full loan repayment or alternative capital solutions to August 21, 2026. Additionally, lenders reduced the minimum liquidity covenant requirement from $6.25 million to $3.0 million. BioXcel Therapeutics operates in the biotechnology industry, focusing on the development of pharmaceutical treatments for central nervous system disorders.